Pharma Rights Issue Documentation & Shareholder Registry Service
The Opportunity
Indian pharma companies are issuing record rights offerings (₹47,280 Cr in FY26 vs ₹15,760 Cr in FY25) to raise capital amid supply chain pressures. Small retail shareholders in tier-2/3 cities lack local support to understand rights applications, complete forms, verify eligibility, and submit paperwork within tight deadlines — creating friction and missed subscriptions.
Market Size
₹850 Cr addressable market — estimated from 15-20 major pharma rights issues annually × 50,000-100,000 retail shareholders per issue × ₹500-1000 per shareholder service across metros and tier-2 cities
Business Model
Physical agent visits retail pharma shareholders at home or office, explains rights issue benefits, verifies shareholding, completes application forms, collects cheques/bank details, and submits within deadline. Charge ₹500-₹800 per shareholder visit. Partner with 2-3 pharma investor relations teams per year for bulk assignments.
₹500-800 per shareholder (₹25,000-40,000 revenue per rights issue with 50 shareholders)Bulk contract incentive from pharma IR teams: ₹2-5 lakh per issue for managing 200+ shareholdersRepeat business: 3-4 rights issues per major pharma company over 18 months
Your 30-Day Action Plan
Identify 5-10 major pharma companies (Cipla, Sun, Lupin, Dr Reddy's, Aurobindo) and their shareholder registrars. Contact investor relations teams with a pitch: 'We handle retail shareholder application completion for upcoming rights issues.'
Get a list of 100-200 retail pharma shareholders from a registrar (publicly available or via registrar partnership). Create a simple visit template with checklist for forms, bank details, shareholding verification.
Do 5 pilot shareholder visits in your city, document success stories (forms submitted on time, no rejections), get testimonials from registrar about submission quality.
Pitch results to pharma company's investor relations head for the next rights issue (usually announced within 2-3 months). Lock in contract for 50-100 shareholder visits at ₹600 each.
Compliance & Regulatory Angle
No specific license required. GST registration optional until ₹40 lakh turnover. Treat as 'professional services' under GST 998511 (if registered). Must maintain shareholder data confidentiality — simple data protection agreement with pharma company. SEBI allows third-party shareholder support; not regulated activity.
Regulatory References
Governs rights issue procedure and shareholder eligibility verification requirements
Protects shareholder data confidentiality and prevents misuse of personal financial information
Covers financial confidentiality and fraud prevention in document handling
Tax classification for shareholder services once turnover exceeds ₹40 lakh
Ready to Act on This Opportunity?
Generate a 7-step execution plan — validate the market, build the MVP, model the financials, map the risks, and ship in 30 days.